AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21889304 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Patient Information Leaflet (PIL)
Number of subjects: 0
Study 21889304 — intervention group
Group type: COMPARATOR
Intervention: Full Patient Information Leaflet (PIL)
Number of subjects: 0
Study 20352147 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplementation
Number of subjects: 41
Study 17510864 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (Group 1)
Number of subjects: 49
Study 17510864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (Group 2)
Number of subjects: 49
Study 17510864 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft plus mitomycin C (Group 3)
Number of subjects: 49
Study 15746633 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin administration before surgery
Number of subjects: 94
Study 15746633 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin (control) group
Number of subjects: 94
Study 12153407 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of cold using an ice-water pack
Number of subjects: 0
Study 12153407 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of heat using a hot water bottle
Number of subjects: 0
Study 9808219 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg RRR-alpha-tocopheryl acetate
Number of subjects: 40
Study 7649709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross Training (CT)
Number of subjects: 11
Study 7649709 — intervention group
Group type: COMPARATOR
Intervention: Run Training (RT)
Number of subjects: 11
Study 2663749 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (without ISA)
Number of subjects: 20
Study 2663749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (with marked ISA)
Number of subjects: 20
Study 2663749 — intervention group
Group type: COMPARATOR
Intervention: Timolol and Pindolol
Number of subjects: 20
Study 1266422 — intervention group
Group type: EXPERIMENTAL
Intervention: D(‐)penicillamine (900 mg) plus salicylate (1500 mg)
Number of subjects: 17
Study 1266422 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (10 mg) plus salicylate (1500 mg)
Number of subjects: 17
Study 30598358 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills (HCS)
Number of subjects: 70
Study 28432468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen administered over 15, 60, or 120 minutes
Number of subjects: 12
Study 25545331 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (600 mg/d ubiquinol) with simvastatin 20 mg/d
Number of subjects: 120
Study 25545331 — intervention group
Group type: COMPARATOR
Intervention: Placebo with simvastatin 20 mg/d
Number of subjects: 120
Study 25545331 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 120
Study 23470188 — intervention group
Group type: COMPARATOR
Intervention: Gym membership
Number of subjects: 410
Study 23470188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym + PA education
Number of subjects: 410
Study 23470188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym + time during the workday
Number of subjects: 410
Study 23470188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym + education + time
Number of subjects: 410
Study 22013704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention conducted by schoolteachers who attended a nutritionist-led training course (group-1)
Number of subjects: 813
Study 22013704 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education intervention conducted by schoolteachers who performed a self-training course (group-2)
Number of subjects: 813
Study 18628521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone administration (T(4) 50 microg and T(3) 0.67 microg/kg.d)
Number of subjects: 8
Study 18628521 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study 16950363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaperonin 10 (5 mg)
Number of subjects: 23
Study 16950363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaperonin 10 (7.5 mg)
Number of subjects: 23
Study 16950363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaperonin 10 (10 mg)
Number of subjects: 23
Study 16950363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaperonin 10 (all doses)
Number of subjects: 23
Study 12363191 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 254
Study 12363191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study 10481501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft group (patients with unilateral cleft lip and palate)
Number of subjects: 90
Study 10481501 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without cleft)
Number of subjects: 90
Study 8942005 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin injection using buffered regular insulin
Number of subjects: 5
Study 8942005 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin injection using unbuffered regular insulin
Number of subjects: 5
Study 8942005 — intervention group
Group type: COMPARATOR
Intervention: Isophane insulin injected at bedtime
Number of subjects: 5
Study 1723684 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor for 3 days postoperatively
Number of subjects: 22
Study 1723684 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapeutic agent)
Number of subjects: 22
Study 1723684 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor
Number of subjects: 22
Study 7041937 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg a day)
Number of subjects: 20
Study 7041937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (5 mg a day)
Number of subjects: 20
Study 7041937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of indapamide and bendrofluazide
Number of subjects: 20
Study 29462248 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PBC)
Number of subjects: 215
Study 29462248 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (NPBC)
Number of subjects: 215
Study 28197774 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteal block + general anaesthesia (group P)
Number of subjects: 54
Study 28197774 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia without popliteal block (group C)
Number of subjects: 54
Study 26423425 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 2 days per week (G2X)
Number of subjects: 27
Study 26423425 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 3 days per week (G3X)
Number of subjects: 27
Study 26423425 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (both groups)
Number of subjects: 27
Study 23640829 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Drop Stimulator (FDS)
Number of subjects: 197
Study 23640829 — intervention group
Group type: COMPARATOR
Intervention: Ankle Foot Orthosis (AFO)
Number of subjects: 197
Study 21254041 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene (Prolene(®))
Number of subjects: 456
Study 21254041 — intervention group
Group type: COMPARATOR
Intervention: Polydioxanone (PDS(®))
Number of subjects: 456
Study 18258988 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapy based on pretreatment clinical extent of disease and pathologic extent after chemotherapy
Number of subjects: 0
Study 18258988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 0
Study 18258988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiation
Number of subjects: 0
Study 18258988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest-wall and regional nodal radiation
Number of subjects: 0
Study 18258988 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 0
Study 16474939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound (30 mW/cm2, 20 min/day)
Number of subjects: 21
Study 16474939 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 21
Study 12924753 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 9
Study 12924753 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (25 mg)
Number of subjects: 9
Study 10994901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 439
Study 10994901 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 439
Study 10994901 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 439
Study 9481995 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/night)
Number of subjects: 10
Study 9481995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 mg/night)
Number of subjects: 10
Study 8180855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn-DPDP enhanced MRI
Number of subjects: 29
Study 8180855 — intervention group
Group type: COMPARATOR
Intervention: DBCT
Number of subjects: 29
Study 3371084 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide/amiloride (40 mg frusemide plus 5 mg amiloride per tablet)
Number of subjects: 40
Study 3371084 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide/potassium chloride (0.5 mg bumetanide plus 573 mg slow‐release potassium chloride per tablet)
Number of subjects: 40
Study 30201040 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Triple P Positive Parenting Programme plus treatment as usual (TAU)
Number of subjects: 66
Study 30201040 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 66
Study 26816607 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day duloxetine
Number of subjects: 258
Study 26816607 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day duloxetine
Number of subjects: 258
Study 24576381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 times a week for 8 weeks, 45-60 minutes at 60-70% heart rate reserve)
Number of subjects: 53
Study 24331628 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with iodine [131I] metuximab injection
Number of subjects: 60
Study 24331628 — intervention group
Group type: COMPARATOR
Intervention: TACE therapy alone (Control Group)
Number of subjects: 60
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM/capecitabine
Number of subjects: 4237
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM/cisplatin
Number of subjects: 4237
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM/5-fluorouracil
Number of subjects: 4237
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM/irinotecan
Number of subjects: 4237
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM/oxaliplatin
Number of subjects: 4237
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (good PS)
Number of subjects: 4237
Study 20147334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (poor PS)
Number of subjects: 4237
Study 18077217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus gemcitabine and cisplatin
Number of subjects: 84
Study 18077217 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin
Number of subjects: 84
Study 16632815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron (1 mg)
Number of subjects: 220
Study 16632815 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 220
Study 12139908 — intervention group
Group type: EXPERIMENTAL
Intervention: St George Outreach Maternity Project (STOMP)
Number of subjects: 1089
Study 12139908 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1089
Study 12139908 — intervention group
Group type: COMPARATOR
Intervention: Unknown midwife during labour
Number of subjects: 1089
Study 12139908 — intervention group
Group type: COMPARATOR
Intervention: Postnatal care
Number of subjects: 1089
Study 9793287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg daily for 14 days)
Number of subjects: 20
Study 9793287 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg daily for 15 days)
Number of subjects: 20
Study 7759669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 0
Study 2518679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (NGO, 18 mg)
Number of subjects: 22
Study 2518679 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 22
Study 333557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 10
Study 333557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 10
Study 333557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6758932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg tiapamil intravenously
Number of subjects: 57
Study 6758932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30969142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower sodium chloride diet (6 g/d)
Number of subjects: 15
Study 30969142 — intervention group
Group type: COMPARATOR
Intervention: Higher sodium chloride diet (12 g/d)
Number of subjects: 15
Study 29368069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with red, 655-nm laser light, 150 mW, 2 J/cm2, on days 0, 3, 5, and 7
Number of subjects: 11
Study 29368069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser therapy)
Number of subjects: 11
Study 26784710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vistakon Acuvue Bifocal (bifocal soft contact lenses [BFSCLs])
Number of subjects: 86
Study 26784710 — intervention group
Group type: COMPARATOR
Intervention: Vistakon Acuvue 2 (single‐vision soft contact lenses [SVSCLs])
Number of subjects: 86
Study 23763411 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Mothers on the Move (MOMs) intervention
Number of subjects: 139
Study 23763411 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 139
Study 21880544 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 8
Study 21880544 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 8
Study 21880544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19546072 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day orally for 2 weeks before surgery)
Number of subjects: 30
Study 19546072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 30
Study 17635062 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic warming using the Inditherm warming mattress set at 40 degrees C
Number of subjects: 33
Study 17635062 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic and fluid resuscitation (Control)
Number of subjects: 33
Study 15726917 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (1 mg oral)
Number of subjects: 34
Study 15726917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12046257 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder form of calcium carbonate (Vitacalcin pulvis)
Number of subjects: 24
Study 12046257 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablet (Calcium 500 mg Pharmavit)
Number of subjects: 24
Study 12046257 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (250 ml enriched with milk calcium complex)
Number of subjects: 24
Study 9468366 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV 200 mg three times daily plus p24‐VLP (500 microg) in intramuscular alum monthly
Number of subjects: 61
Study 9468366 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV 200 mg three times daily plus intramuscular administration of alum adjuvant monthly
Number of subjects: 61
Study 9468366 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules plus p24‐VLP (500 microg) in intramuscular alum monthly
Number of subjects: 61
Study 7589843 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fasting insulin (quartile 4, high)
Number of subjects: 714
Study 7589843 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased delta I30/delta G30 (quartile 1, low)
Number of subjects: 714
Study 7589843 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fasting insulin and decreased delta I30/delta G30
Number of subjects: 714
Study 2202010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion for 12 hours during arteriography
Number of subjects: 60
Study 2202010 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during arteriography
Number of subjects: 60
Study 326133 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran 70 (Macrodex)
Number of subjects: 235
Study 326133 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextran 40 (Rhemacrodex)
Number of subjects: 235
Study 326133 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in 0.9% saline (Control)
Number of subjects: 235
Study 31977595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine (2DR)
Number of subjects: 293
Study 31977595 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (3DR)
Number of subjects: 293
Study 31243557 — intervention group
Group type: EXPERIMENTAL
Intervention: Occiput-to-wall distance (OWD)
Number of subjects: 158
Study 28041700 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg once daily for six months
Number of subjects: 80
Study 28041700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20mg once daily for six months
Number of subjects: 80
Study 28041700 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 80
Study 26180950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafeteria-based intervention with signage promoting water and disposable cups near water sources
Number of subjects: 10
Study 23613224 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TE)
Number of subjects: 90
Study 23613224 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise (GE)
Number of subjects: 90
Study 23613224 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (HE)
Number of subjects: 90
Study 21562072 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wP, 80 mg/m(2)/week)
Number of subjects: 165
Study 21562072 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + carboplatin (wP + C, AUC 5 mg/ml/min every 4 weeks)
Number of subjects: 165
Study 21562072 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + topotecan (wP + wT, 3 mg/m(2)/week)
Number of subjects: 165
Study 21562072 — intervention group
Group type: COMPARATOR
Intervention: Control (monotherapy vs combination therapy)
Number of subjects: 165
Study 19686934 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS
Number of subjects: 160
Study 19686934 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 160
Study 17049882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating spot method with instructions to report the instant when the finger movement was initiated
Number of subjects: 0
Study 17049882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating spot method with instructions to report the instant when the finger movement was completed
Number of subjects: 0
Study 17049882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating spot method with altered physical characteristics of the spot or clock face
Number of subjects: 0
Study 17049882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating spot method with altered instructions given to the participant
Number of subjects: 0
Study 17049882 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses made by different subjects
Number of subjects: 0
Study 15161770 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 54
Study 15161770 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 54
Study 15161770 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 54
Study 11862589 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg, two 20 mg bolus injections on days 0 and 4)
Number of subjects: 381
Study 11862589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 11862589 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg)
Number of subjects: 381
Study 10215945 — intervention group
Group type: EXPERIMENTAL
Intervention: Malmö Treatment Model protocol including immunoadsorption, cyclophosphamide (12-15 mg/kg bw intravenously for 2 days, then 2-3 mg/kg bw orally for 8-10 days), and intravenous gammaglobulin (0.4 g/kg bw daily for 5 days)
Number of subjects: 23
Study 10215945 — intervention group
Group type: EXPERIMENTAL
Intervention: Malmö Treatment Model protocol
Number of subjects: 23
Study 7611753 — intervention group
Group type: EXPERIMENTAL
Intervention: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU and MMC
Number of subjects: 14
Study 7611753 — intervention group
Group type: COMPARATOR
Intervention: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU and MMC
Number of subjects: 14
Study 7611753 — intervention group
Group type: EXPERIMENTAL
Intervention: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU for 7 days
Number of subjects: 14
Study 7611753 — intervention group
Group type: COMPARATOR
Intervention: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU for 7 days
Number of subjects: 14
Study 2307275 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide (25%) medicated occlusive dressing
Number of subjects: 0
Study 2307275 — intervention group
Group type: COMPARATOR
Intervention: Control-treated skin
Number of subjects: 0
Study 80632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod (5 daily subcutaneous injections)
Number of subjects: 53